Topical use of calcitriol 3 microg/g ointment in the treatment of mild-to-moderate psoriasis: results from an open-label study

J Eur Acad Dermatol Venereol. 2005 Nov:19 Suppl 3:11-3. doi: 10.1111/j.1468-3083.2005.01331.x.

Abstract

Background: Calcitriol is the active metabolite and hormonal analogue of vitamin D3. It is widely used for the topical treatment of psoriasis showing good tolerability and effectiveness.

Objectives: To assess the efficacy, tolerability and safety of calcitriol 3 microg/g ointment in mild to moderate plaque psoriasis involving sensitive areas.

Methods: Sixty patients with a body surface area < 35% were enrolled into a prospective open label clinical study. Patients were treated for 12 weeks with a twice daily calcitriol 3 microg/g topical ointment application. Efficacy and safety were assessed during the therapy and during a 6-month follow-up period.

Results: The study demonstrated a high clinical remission rate which progressively increased throughout therapy (11.6% at week 4, 28.3% at week 8 and 63.3% at week 12). No serious adverse events and clinically relevant changes of calcium/phosphorus homeostasis were reported.

Conclusions: The study suggests that calcitriol 3 microg/g ointment, applied twice daily, is an effective topical treatment for chronic psoriatic plaques involving less than 35% of the body surface and sensitive areas.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Administration, Topical
  • Adolescent
  • Adult
  • Aged
  • Calcitriol / therapeutic use*
  • Child
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Ointments
  • Prospective Studies
  • Psoriasis / diagnosis*
  • Psoriasis / drug therapy*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Ointments
  • Calcitriol